Drug Information Association 18th Annual EuroMeeting Hosts Largest Attendance Ever
2,500+ International Professionals from Industry, Academia, and Regulatory Agencies Convene in Paris: 17 Meeting Tracks Including 400+ Speakers, 170+ Exhibits and 14 Tutorials
PARIS – The Drug Information Agency (DIA) kicked off its 18th Annual EuroMeeting at Le Palais des Congres with record-breaking attendance. An international, neutral forum for the exchange of multi-disciplinary drug information, the conference will address the latest developments in important European initiatives, including paediatrics, advanced therapies, the technology platform, pharmacogenomics, pharmacovigilance and risk management planning.
"With a bold agenda, including sessions on the revised Pharmaceutical Legislation, the 18th Annual DIA EuroMeeting is a 'not to miss' event," said David Maola, executive director of DIA. "The meeting will address a multitude of issues that will help improve the lives of people around the world."
The 18th Annual EuroMeeting will feature over 170 exhibits and 400 speakers presenting on topics organised into 17 session tracks:
- Innovation and Competitiveness in Global Medicines Development
- R & D – Are There New Molecular and Nonclinical Paradigms?
- Advanced Therapies in Biologics
- Promises and Realities of Pharmacogenomics and New Technologies
- Clinical Research – European Focus versus Global and Development Constraints
- Investigational Clinical Research
- Challenges of the Revised Pharma Regulatory Environment
- The Patient's Voice in Europe
- Medical Information
- Statistics
- Data Management
- Global Pharmacovigilance and Risk Management
- Quality and Quality Systems – GCP and GMP Issues
- Project Management – Outsourcing and Alliances
- Bringing Authorised Medicines to the Market – New Challenges
- Generics and OTC
In addition to 14 tutorials led by a variety of skilled professionals, keynote speakers Georgette Lalis, European Commission, DG Enterprise and Industry, and Jean-Francois Dehecq, sanofi-aventis, will be featured at the event.
On the evening of Tuesday, March 7, there will be a French Agency Satellite Meeting on "The Involvement of France in The European Networks for Evaluation and Monitoring of Health Products," featuring an opening and plenary by Jean Marimbert, General Director of Afssaps, France, followed by a Round Table Discussion on the Common Vision on Clinical Trials in France with Representatives of LEEM, INSERM, Afssaps and French hospital networks.
For more information on DIA's 18th Annual EuroMeeting, please download the programme at http://www.diahome.org/Content/Events/06101.pdf.
About the Drug Information Association (DIA)
The Drug Information Association serves more than 23,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, Pa., USA, and with offices in Basel, Switzerland and Tokyo, Japan, the association is led by its volunteer-based board of directors and executive management team. For more information, visit www.diahome.org, call +1.215.442.6100, or in Europe +41.61.225.5151.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
